RxDoctor Payments Data

Timothy Kresowik, MD

Urology · Davenport, IANPI 1831308840

Payments from drug & device makers

$801in general payments, 2019–2025

Across 18 payments — averaging $44.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$239
  • Isoray, Inc$87
  • Valencia Technologies Corporation$84
  • Intuitive Surgical$83
  • Progenics Pharmaceuticals, Inc.$83
  • Astellas Pharma US Inc$55
  • plus $170 from 9 others

What the payments were for

  • Food & beverage$55970%
  • Education$30%
  • Gifts$23930%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$801 in reported general payments places this provider in the 35th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$372,594
Medicare patients
587
Services billed
12,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix134$358,042
XtandiEnzalutamide15$209,442
NubeqaDarolutamide17$186,249
MyrbetriqMirabegron99$56,452
GemtesaVibegron19$8,878
Tamsulosin Hcl318$3,533
Finasteride181$1,807
Solifenacin Succinate62$1,362
Potassium Citrate ErPotassium Citrate12$1,321
NitrofurantoinNitrofurantoin Macrocrystal64$1,243
Trimethoprim13$850
Cephalexin69$405
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$260
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim63$258
Doxycycline Monohydrate20$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$55$265,894114 claims
BayerNubeqa$11$186,24917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 114 urology providers in Iowa.

Other urology in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →